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serum creatinine declined gradually to 4.0 mg/dL, the
urinary protein excretion ranged between 0.5 and 2.0 g/
day, and the patient developed hypertension for which
she received minimal treatment. Evaluation for amenor-
rhea revealed low follicle-stimulating hormone (FSH)
levels consistent with partial pituitary destruction, which
presumably had occurred during the immediate postpar-
tum period.
The patient’s renal function had remained stable for
years 4 through 8 after the acute renal failure, but the
serum creatinine slowly rose over the ensuing 7 years.
Uremic symptoms developed when the serum creatinine
reached 8.7 mg/dL, 15 years after the episode of acute
CASE PRESENTATION postpartum renal failure, and ambulatory peritoneal di-
alysis was initiated.A 26-year-old woman was transferred to Tufts-New
England Medical Center from another hospital with a
diagnosis of acute renal failure complicating abruptio
DISCUSSIONplacentae. Emergency caesarean section delivered a still-
Dr. Barry M. Brenner (Samuel A. Levine Professorborn child 2 days prior to transfer. Immediately postpar-
tum, the patient developed hypotension and she re- of Medicine, Harvard Medical School, and Director
mained oliguric for 16 days. An abdominal radiograph Emeritus, Renal Division, Brigham and Women’s Hospi-
revealed an 11.5 cm right kidney and a 12.5 cm left tal, Boston, Massachusetts): This woman with severe
kidney. The blood urea nitrogen (BUN) and serum creat- acute renal failure occurring in the immediate postpar-
inine levels rose as high as 128 and 18.9 mg/dL, respec- tum period in association with abruptio placentae was
tively. Hemodialysis was performed on three occasions discussed by me in a previous Nephrology Forum in 1983
during the period of oliguria. The urine output subse- [1]. Her case illustrates a problem of transient, incom-
quently increased to a high of 1900 mL by the 29th plete recovery of renal function followed by an inexora-
hospital day. The patient was discharged 5 weeks after ble decline requiring permanent renal replacement ther-
admission with a serum creatinine of 12.6 mg/dL. apy. The underlying pathophysiologic processes include
Nine months after the episode of acute renal failure, a bilateral cortical necrosis, hyperfiltration in surviving
percutaneous renal biopsy yielded only medullary tissue nephrons, and eventual progressive damage to these sur-
with nonspecific degenerative changes, a marginal focus
viving units as long-term consequences of hemodynamicof necrosis, and numerous protein casts. At that time,
and non-hemodynamic adaptations to her initial neph-an abdominal radiograph showed a 10 cm right kidney
ron loss.and an 11 cm left kidney. Over the next 4 years, the
My purpose today is to review the ample progress that
has been made since 1983 in our understanding of the
Key words: chronic renal failure, end-stage renal disease, hypertension, mechanisms of progressive nephron loss and in the thera-glomerular injury, ACE inhibitors, angiotensin receptor blockers, dia-
betic nephropathy, proteinuria peutic approaches to interrupting this progression. Based
on this progress, it is entirely likely that current treatment
The Nephrology Forum is funded in part by grants from Amgen,
strategies would have markedly delayed and even mightIncorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
rated; and Bristol-Myers Squibb Company. have prevented this patient from ever reaching end-stage
renal disease (ESRD). 2003 by the International Society of Nephrology
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Table 1. Risk factors for progression of renal disease in the literature have addressed this intriguing question
[4–6].Persistent activity of underlying disease
Common amplifiers of risk A variety of measures slow the progression of experi-
Suboptimal control of hypertension mental renal disease, and alleviation of glomerular capil-Proteinuria 1 g/day
lary hypertension appears to be the common denomina-Urinary tract obstruction/reflux/infection
Analgesics or other nephrotoxins tor. Glomerular capillary hypertension is maintained by
Marked reduction in nephron number (congenital or acquired) angiotensin-dependent mechanisms, via increased sys-Low birth weight
temic blood pressure as well as intrarenal, efferent arteri-Other factors promoting increases in glomerular pressures/flows
High-protein diet olar vasoconstriction. Angiotensin-converting enzyme
Diabetes mellitus (ACE) inhibitors and angiotensin receptor blockersPregnancy
(ARBs) are highly effective in reversing glomerular cap-Hyperlipidemia
Chronic anemia [56] illary hypertension and in retarding disease progression.
Cigarette smoking [57] In rats with experimental renal disease, we observedObesity [58]
that for an equivalent systemic blood pressure–lowering
effect, ACE inhibitors reduced glomerular capillary
pressure and slowed the rate of renal disease progression,
whereas with a combination of hydralazine, reserpine,Mechanisms
and a diuretic, glomerular hypertension persisted and
After glomerular filtration rate (GFR) falls below disease progression continued unabated [7]. Subsequent
about one-half of normal in humans, a progressive fur- studies consistently demonstrated renal protection with
ther loss of function ensues, even when, as in the case inhibitors of the renin-angiotensin system (RAS) in a
presented, the original disease becomes inactive [2] (Ta- variety of experimental models of renal disease in which
ble 1). This phenomenon is modeled by partial ablation glomerular hypertension was initially present [8].
of renal mass in rats, which leads to proteinuria, systemic Although angiotensin II has emerged as a central me-
hypertension, glomerulosclerosis, and eventual renal diator of the glomerular hemodynamic changes associ-
failure. In response to reduced renal mass, surviving ated with progressive renal injury, experimental studies
nephrons undergo adaptations in structure and function, have revealed several non-hemodynamic effects of an-
including increases in single-nephron GFR, to meet ex- giotensin II that also might be important in renal disease
cretory demands. We proposed that maladaptive glomer- progression. These non-hemodynamic effects include
ular hemodynamic changes associated with increased sin- mesangial cell proliferation and the induction of trans-
gle-nephron GFR initiate and perpetuate glomerular injury forming growth factor- (TGF-) expression, both of
following renal mass ablation, and we suggested that which result in increased synthesis of extracellular ma-
similar events occur when nephrons are lost through trix; stimulation of plasminogen activator inhibitor-1
disease [3]. In response to reduced total GFR, increased (PAI-1) production by endothelial and vascular smooth
single-nephron GFR results from elevated glomerular muscle cells; macrophage activation and infiltration; and
flows and pressures in surviving nephrons. Raised glo- adrenal production of aldosterone, a recently recognized
merular hydraulic pressure (glomerular hypertension) contributor to renal injury [reviewed in 9 and 10].
appears to be the major effector of glomerular injury
Clinical trials of renoprotectionfollowing renal mass reduction. In addition to the detri-
mental effects of acquired nephron loss, severe inborn Dietary approaches. More than 50 years ago, Addis
deficits in total nephron endowment also cause progres- [11] speculated that the severity of chronic renal disease
sive glomerular injury. Individuals born with greatly re- could be ameliorated by reducing the excretory burden
duced nephron number, that is, congenital oligomega- for nitrogen through dietary protein restriction. Indeed,
nephronia, eventually develop glomerulosclerosis and in experimental animals, dietary protein restriction re-
ESRD [4]. Mice with a congenital shortfall in nephron duces the load of nitrogenous metabolic end products,
number of approximately 20% to 40% also develop hy- abrogates the adaptive changes in remnant nephrons
pertension and glomerulosclerosis in later life. These (that is, glomerular hypertension), and slows progression
observations support the view that extrinsic injury is not of renal disease. Despite the longevity of this hypothesis
a prerequisite for the development of glomerulosclerosis, and unambiguous support from experimental studies,
but that an inadequate endowment of nephrons at birth confirmation of a beneficial effect of protein restriction
per se can lead to hypertension, glomerulosclerosis, and in clinical trials has been elusive [12–14]. However, a
chronic renal failure. If large inborn deficiencies in neph- recent meta-analysis of five randomized, controlled trials
ron number lead to renal failure in young adults, could of protein restriction on the progression of non-diabetic
more subtle deficiencies predispose to age-related glo- renal disease determined that the overall relative risk
for renal failure or death was reduced with protein re-merulosclerosis and/or systemic hypertension? Reviews
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striction, as compared to non-restricted protein intake enalapril versus placebo over 7 years in 94 normotensive
subjects with microalbuminuria and normal renal func-[15]. Likewise, a meta-analysis of five small studies of
diabetics showed that the relative risk of progression tion. If blood pressure treatment was required during
the course of the study, long-acting nifedipine was added.among 108 dietary protein-restricted patients was almost
one-half that of diabetics eating a more liberal protein Enalapril treatment was associated with a small lowering
of blood pressure and stable microalbuminuria over thediet [15].
Pharmacologic approaches. Diabetic nephropathy is 7-year follow-up. By contrast, microalbuminuria in-
creased roughly twofold in the placebo group over thenow the leading cause of ESRD in the United States and
other developed countries. This burden is expected to same 7-year period. Whereas renal function, assessed by
the reciprocal of serum creatinine, declined progressivelydouble over the next decade and rise even more substan-
tially in the developing world. Studies in rodents showed in the placebo group, reflecting a 16% loss at 7 years, re-
nal function remained stable at baseline levels through-that controlling glomerular capillary hypertension with
ACE inhibitors retards the development of the glomerular out the study in the patients receiving enalapril.
Many other studies of diabetic nephropathy using anti-lesions of experimental diabetic nephropathy [16].
The results of several small studies performed to assess hypertensive drugs were uncontrolled, enrolled rela-
tively few patients, or were too brief. Not all investiga-the effects of antihypertensive treatment in general, and
ACE inhibitors in particular, on the rate of progression tions distinguished between type 1 and type 2 diabetes,
and the wide range of end points used was a reflectionof diabetic nephropathy were reviewed by Mogensen
[17]. Whereas many of these studies appeared to show of the different stages of diabetic nephropathy studied.
In an attempt to extract meaningful information froma favorable response to therapy, none was sufficiently
robust statistically to establish conclusively the value of this heterogeneous database, Kasiske et al [20] per-
formed a meta-analysis of 100 studies that included 2494antihypertensive treatment or ACE inhibition therapy in
diabetic nephropathy. These shortcomings were resolved patients and 11 randomized controlled trials. Using mul-
tiple linear regression analysis techniques, the authorsby the clinical trial entitled The Effect of Angiotensin-
Converting-Enzyme Inhibition on Diabetic Nephropa- concluded that ACE inhibitors were uniquely renopro-
tective in reducing proteinuria and preserving GFR. Bythy [18]. This collaborative study led to the first federally
approved treatment for slowing the progression of renal contrast, the reductions in proteinuria and disease pro-
gression with other antihypertensive agents could be at-disease in the United States. The protocol randomized
407 patients with type 1 diabetes and proteinuria 500 tributed only to reductions in blood pressure. In the
context of the findings of the randomized controlled tri-mg/day to receive either captopril or placebo. Hyperten-
sion or the need for antihypertensive drugs, although als by Lewis et al [18] and Ravid et al [19], conclusions
from this meta-analysis are in accord with the notioncommon, was not an entry requirement. Blood pressure
control was managed independently of the experimental that blockade of the RAS offers a unique therapeutic
advantage for slowing the rate of progression of renaltreatment, using agents other than ACE inhibitors or
calcium-channel blockers. Patients receiving captopril disease and that the specific renoprotective and antipro-
teinuric effects of ACE inhibitors probably reflect thewere, on average, only 48% as likely to double their
serum creatinine when compared with those receiving favorable changes in glomerular hemodynamics induced
by ACE inhibitors, as originally observed in animals.placebo. Captopril treatment was also associated with a
50% reduction in the risk of the combined end points More recently, six other randomized double-blind stud-
ies have compared ACE inhibitors with other drugof death, dialysis, or transplantation. The rate of decline
of creatinine clearance averaged 11% per year with cap- classes in patients with type 2 diabetes and nephropathy
[reviewed in 21]. These studies demonstrated a benefittopril treatment versus 17% in the placebo group. These
striking results provided the first solid clinical evidence of blood pressure reduction on proteinuria and rate of
decline in GFR, but none found superiority of ACEfor effective retardation of nephropathy, in this case due
to type 1 diabetes. inhibition over non-ACE inhibition therapy.
Angiotensin II receptor blockers inhibit the RAS byMost diabetic patients who develop ESRD have type
2 diabetes. This is not surprising, given its approximate blocking angiotensin II subtype 1 (AT1) receptors. Thus
ACE inhibitors and ARBs differ in their effects on the20-fold greater prevalence over type 1. Type 2 diabetic
patients develop glomerular hyperfiltration, microalbu- RAS in ways that might be therapeutically relevant. First,
ACE inhibitors can inhibit only ACE-dependent angio-minuria, and macroalbuminuria followed by progressive
declines in GFR, much as in type 1 diabetic patients and tensin II production, whereas ARBs block the effects of
angiotensin II from any source at the receptor level.with essentially the same time course. Renal protection
with ACE inhibitors in type 2 diabetics was observed by Even in the presence of ACE inhibition, conversion of
angiotensin I to angiotensin II can be catalyzed by otherRavid et al [19] in a small multicenter, double-blind,
randomized controlled trial that compared the effects of proteases, including chymase and other serine proteases
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(non-ACE inhibitor–sensitive). Despite these theoreti- conventional antihypertensive therapy, excluding ACE
inhibitors and ARBs. The dose of losartan was 50 orcal differences, experimental studies have shown that
ACE inhibitors and ARBs produce similar improve- 100 mg once daily; 71% of the patients received 100 mg
daily by the end of the study. Baseline characteristicsments in glomerular hemodynamics and afford equiva-
lent renoprotection in a variety of experimental models were similar in the two treatment groups. Losartan treat-
ment reduced the relative risk of the primary compositeof renal disease [8].
Two large, prospective, multicenter, randomized trials end point by 16% (P  0.024). The major benefit ap-
peared to accrue from the renal components of the com-recently showed that interruption of the RAS with ARBs
in type 2 diabetic patients with overt nephropathy delays posite end point. The risk of doubling of serum creati-
nine, ESRD, and combined end point of ESRD or deaththe progression of renal disease [22, 23]. The Irbesartan
Type 2 Diabetic Nephropathy Trial (IDNT) evaluated were decreased by 25% (P  0.002), 28% (P  0.006),
and 20% (P 0.010), respectively. The RENAAL studythe effects of the ARB irbesartan on renal and cardiovas-
cular morbidity and mortality versus either conventional is thus the only investigation to date that specifically
reduced the risk of ESRD in diabetes, in this case withtherapy (placebo group) or the calcium-channel blocker
amlodipine in 1715 subjects [22]. The primary composite losartan. Proteinuria, as evaluated by the urine albu-
min:creatinine ratio, decreased by 34% in the losartanend point of the study was the time to a first event,
namely, doubling of baseline serum creatinine, ESRD arm and increased slightly in the placebo group (P 
0.001). Losartan slowed the rate of loss of renal function[renal transplantation, need for dialysis, or serum creati-
nine530 mol/L (6.0 mg/dL)], or death (all-cause mor- by 18% relative to placebo as assessed by the reciprocal
of serum creatinine (median slope 0.056 dL/mg/yeartality). The secondary composite end point was again
time to a first event, namely, cardiac fatality or non-fatal with losartan versus 0.069 with placebo, P  0.01). No
significant difference was observed between the treat-myocardial infarction, hospitalization for heart failure,
stroke, above-the-ankle amputation, or revascularization ment and placebo arms for the secondary composite end
point of cardiovascular morbidity and mortality, or most(cardiac, carotid, peripheral vascular). Baseline charac-
teristics were similar in the three treatment groups. For of the cardiovascular components except first hospital-
ization for heart failure, where a significant risk reductionsubjects receiving irbesartan, the adjusted relative risk
of reaching the primary end point was 19% lower than of 32% (P  0.005) was observed in the losartan arm.
Renal and cardiovascular end points are often compet-placebo (P 0.02) and 23% lower than amlodipine (P
0.006). The relative risk of doubling of serum creatinine ing, but a time-to-event analysis of the competing ESRD,
myocardial infarction, stroke, or all-cause mortality endwas 29% lower in the irbesartan group versus placebo
(P  0.009) and 39% lower versus amlodipine (P  points revealed a 21% risk reduction with losartan.
Again, these consistent benefits of losartan in the RE-0.001). The study found no significant difference between
placebo and amlodipine in the primary composite end NAAL study were above and beyond effects that could
be attributed to measured reductions in blood pressurepoint. The relative risk of ESRD was 17% lower in those
receiving irbesartan compared with placebo and 24% per se. Thus, the IDNT and RENAAL studies demon-
strate that ARBs delay ESRD, death, and at least onelower compared with amlodipine, but these differences
did not achieve statistical significance. The secondary major cardiovascular morbidity in type 2 diabetics.
Several studies investigated the potential of ACE in-cardiovascular outcomes did not show statistical differ-
ences among the various arms of the IDNT study. Pro- hibitors to afford renoprotection in non-diabetic forms
of renal disease. Maschio et al [24] randomly assignedteinuria was reduced an average of 33% in the irbesartan
arm compared with 6% and 10% in the amlodipine and 583 patients with renal disease of diverse cause to treat-
ment with benazepril or placebo. After 3 years of follow-placebo arms, respectively. The more favorable renal
outcomes in the irbesartan group were in excess of effects up, the study found a 53% reduction with ACE inhibitor
treatment in the risk of reaching the combined end pointdirectly attributable to blood pressure control.
The Reduction of Endpoints in NIDDM with the An- of doubling of the baseline serum creatinine or the need
for dialysis. However, a significantly lower blood pres-giotensin II Antagonist Losartan (RENAAL) study [23]
was undertaken to determine whether losartan reduces sure among patients receiving an ACE inhibitor versus
placebo made it difficult to separate the beneficial effectsthe number of patients with type 2 diabetes experiencing
a doubling of serum creatinine, ESRD, or death as com- of lowering of blood pressure from any unique effects
of ACE inhibition.pared to placebo-treated subjects. The primary and sec-
ondary end points of the study were similar to those in By contrast, in the Ramipril Efficacy in Nephropathy
(REIN) study [25], 352 patients with non-diabetic renalIDNT, but RENAAL was of longer average duration
and had larger numbers of patients in its two study arms. disease randomly assigned to receive either the ACE
inhibitor ramipril or placebo achieved similar controlIn RENAAL, 1513 subjects were randomized to receive
either losartan or placebo once daily on a background of of blood pressure. Among patients with proteinuria of
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3 g/day at baseline, the study was stopped early because inhibitors. Therefore, even in the absence of clinical trial
evidence of the renoprotective effects of ARB, clinicalthe ACE inhibitor significantly lowered the rate of de-
cline in GFR (0.53 versus 0.88 mL/min/month). In a experience supports their use as an alternative in patients
who are unable to tolerate ACE inhibitors because ofsecond phase of the study, patients who initially received
placebo were switched to the ACE inhibitor, and those side effects. Finally, the differing effects of ACE inhibi-
tors and ARBs on the RAS imply that in combinationalready receiving an ACE inhibitor continued treatment
[26]. Consistent with the findings in the first 2-year phase they might have additive or even synergistic effects, and
early evidence supports this contention [reviewed in 8,of the study, those switched from placebo to an ACE
inhibitor enjoyed a significant reduction in the rate of 33, 34].
decline in GFR. In addition, patients continuing ACE
Proteinuriainhibition showed a further reduction in the rate of GFR
decline, to levels similar to those associated with normal Proteinuria traditionally has been regarded as a
marker of glomerular barrier integrity. The extent ofaging. Indeed, from 36 to 54 months of follow up, no
patients in the latter group reached ESRD, and a small proteinuria therefore has been taken as an indicator of
glomerular disease severity. However, proteinuria pernumber of patients experienced a rise in GFR after pro-
longed treatment [27]. The same researchers followed se also might contribute to progressive renal injury. In
the REIN study, higher baseline proteinuria was associ-186 other REIN study patients with proteinuria at base-
line less than 3 g/day for a median of 31 months after ated with more rapid rates of decline in GFR, and among
patients with initial proteinuria of3 g/day, ACE inhibi-randomization [28]. Similar to the findings among pa-
tients in the REIN study with more severe baseline pro- tion reduced proteinuria to an extent that correlated
inversely with the subsequent rate of GFR decline [25].teinuria, ACE inhibition significantly reduced the inci-
dence of ESRD, particularly among those with a GFR Furthermore, in the Modification of Diet in Renal Dis-
ease (MDRD) study, a reduction in proteinuria, inde-of less than 45 mL/min at baseline.
A recent patient-based meta-analysis of 1860 non-dia- pendent of blood pressure, was associated with slower
progression of renal disease [12–14]. Experimental ob-betic subjects from 11 randomized ACE inhibitor versus
placebo treatment trials also concluded that ACE inhibi- servations suggest mechanisms whereby an excess of fil-
tered proteins could contribute to renal damage. Cultur-tion is more effective than other antihypertensive treat-
ment regimens in slowing disease progression and reduc- ing tubule epithelial cells in the presence of a variety of
plasma proteins induces production of pro-inflammatorying proteinuria [29]. A similar conclusion emerges from
the African American Study of Kidney Disease and Hy- cytokines and extracellular matrix proteins; these re-
sponses might contribute to tubulointerstitial fibrosis. Inpertension (AASK) trial in hypertensive African-Ameri-
cans. Ramipril proved more renoprotective than either vivo, proteinuria induced by protein overload is associ-
ated with the renal expression of cell adhesion moleculesamlodipine or metoprolol [30]. In addition to also docu-
menting renoprotective effects of ACE inhibition in per- and chemoattractants and results in interstitial inflam-
mation and fibrosis [35–37]. Together, these clinical andsons at high cardiovascular risk [31], the recent Heart
Outcomes Prevention Evaluation (HOPE) study re- experimental findings provide support for the hypothesis
that excessive filtration of serum proteins across injuredported a substantial reduction in all-cause and cardiovas-
cular mortality with ramipril versus placebo among 9297 glomerular capillaries directly contributes to progressive
renal damage. The strong association between reductionpatients at increased risk of cardiovascular events [32].
Because cardiovascular disease is the single largest cause in proteinuria and renoprotection in clinical studies im-
plies that the minimization of proteinuria is an importantof morbidity and mortality among patients with chronic
renal disease, the HOPE study data provide a further independent therapeutic goal in renoprotection strate-
gies.rationale for the use of drugs that interrupt the RAS in
patients with renal disease.
Treatment of hyperlipidemiaLarge randomized clinical studies of the renoprotec-
tive effects of ARBs in non-diabetic renal disease are Chronic renal disease is commonly associated with
abnormalities of plasma lipids, characterized by elevatedstill awaited, but preliminary data suggest that ARBs
will be as effective as ACE inhibitors. In small studies, levels of the triglyceride-rich lipoproteins very low-den-
sity lipoproteins (VLDL) and low-density lipoproteinsARBs and ACE inhibitors produced similar antihyper-
tensive and antiproteinuric effects in patients with essen- (LDL), and reduced levels of high-density lipoproteins
(HDL) [38–42]. In addition to placing patients at increasedtial hypertension and in those with chronic renal disease.
One important advantage of ARBs over ACE inhibitors risk of cardiovascular disease, these lipid abnormalities
also might accelerate the progression of renal disease.is their more favorable side effect profile. Angiotensin
receptor blockers are not associated with the cough that In the MDRD study, low serum HDL cholesterol was
an independent predictor of a more rapid decline in GFRoccurs in as many as 40% of patients receiving ACE
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Table 2. A comprehensive strategy for renoprotection[12]. In another study, elevated apolipoprotein B–contain-
in patients with chronic renal disease
ing lipoprotein levels were associated with a more rapid
Intervention Therapeutic goalprogression of renal disease among diabetic and non-
Specific renoprotective therapydiabetic patients [38]. The mechanisms whereby hyper-
ACE inhibitor or ARB treatment Proteinuria 0.5 g/daylipidemia contributes to renal injury include the stimula-
(consider combination therapy GFR decline 2
tion of mesangial cell proliferation, cytokine expression, if goals are not achieved mL/min/year
with monotherapy)and extracellular matrix synthesis, as well as the oxida-
Adjunctive cardiorenal protective therapytion of LDL to form reactive oxygen species [43–45]. Additional antihypertensive therapy 130/80 mm Hg
In experimental studies, the treatment of dyslipidemia (if needed)
Dietary protein restriction 0.6–0.8 g/kg/dayattenuated renal injury [46–50]. Large randomized clini-
Dietary salt restriction 3–5 g/daycal studies are awaited; nevertheless, results from smaller Tight glycemic control in diabetes HbA1C 6.5%
trials [51–54] and the fact that patients with renal disease Reduce elevated calcium-phosphorus Normal values
productare at increased risk of cardiovascular events currently
Lipid-lowering therapy LDL-C 100 mg/dLjustify a policy of active dietary and drug intervention Anti-platelet therapy Thrombosis prophylaxis
for the correction of hyperlipidemia. Consider correction of anemia Hgb 12 g/dL
Smoking cessation Abstinence
Weight control Ideal body weightA comprehensive strategy for renoprotection
Abbreviations are: ACE, angiotensin-converting enzyme; ARB angiotensin
In less than 2 decades, the use of ACE inhibitors receptor blockers; GFR, glomerular filtration rate; HbA1C, hemoglobin A1C;
LDL-C, low-density lipoprotein cholesterol; Hgb, hemoglobin.and ARBs as therapeutic interventions for slowing renal
disease progression has made the giant leap from labora-
tory to universal clinical practice. At best, however, RAS
blockade slows, but does not generally prevent, progres-
provide quite compelling support for disease retardation
sion of renal disease. To achieve more complete long-
in non-diabetic patients with nephropathy [14, 24–30].
term renoprotection, a comprehensive strategy em-
Dr. Jordan J. Cohen (President, Association of Amer-
ploying multiple therapies directed at different aspects
ican Medical Colleges, Washington, DC): I have a related
of the pathogenesis of progressive renal injury is likely
question. I seem to remember that only about one-third
to be required. Moreover, once treatments have been
of patients with diabetes actually enter a trajectory of
introduced, frequent monitoring of blood pressure, pro-
renal disease and progression. There must be somethingteinuria, and GFR is essential so that therapy can be
we can learn from those who do not.escalated until therapeutic goals are achieved. The ap-
Dr. Brenner: I don’t know of any concerted effort toproach suggested in Table 2 is analogous to that applied
address your important question, but I am sure that muchin modern chemotherapeutic strategies for malignancy,
useful information could be gleaned from studying thein which multiple agents are used, and treatment is di-
non-progressors in an effort to determine what it is thatrected toward eradication of disease activity until the
protects them. It’s like the HIV-infected patient whopatient is said to be “in remission.” I should note that
doesn’t develop clinical disease.the recommendations in Table 2 are based on currently
Dr. Cohen: Except there are a lot more of them here.available interventions, and while it is likely that addi-
Dr. Brenner: Yes, absolutely. We do know that nottional renoprotective agents will be needed, it is also true
all diabetics are hypertensive. We do know that the acti-that currently available therapies are not yet applied
vation of the RAS is not as robust in some as in others.optimally to all patients with chronic renal disease. If
We do know that there are polymorphisms for the geneswidely implemented, a comprehensive renoprotective
that encode for the enzymes in the steps of the RASstrategy might not only delay the need for dialysis in
cascade. Some who are expressing more robust angioten-many patients but might actually prevent patients from
sin II formation because of more ACE activity, as in theever progressing to ESRD.
DD isoform as compared to the non-deletion isoform
for that particular ACE gene, might have greater risk.
QUESTIONS AND ANSWERS Similar polymorphisms exist among the profibrotic mole-
cules, adhesion molecules, cytokines, and chemokines.Dr. Norman Levinsky (Professor of Medicine and
There might be many different risk-adverse or risk-sensi-Physiology, Associate Provost, Medical Campus, Boston
tive steps in these pathways about which we know veryUniversity Medical Center, Boston, Massachusetts): Most
little.of the evidence you presented related to diabetic renal
Dr. Ronald D. Perrone (Associate Chief, Division ofdisease. How compelling do you think the evidence is
Nephrology, Tufts-New England Medical Center, Boston,in regard to non-diabetic renal disease?
Dr. Brenner: As I indicated in my presentation, studies Massachusetts): Polycystic kidney disease (PKD) is a pro-
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gressive disease with progression rates in the range of The avidity of angiotensin II to that receptor differs with
these polymorphisms. I cite this as just one possibility5 mL/min/year in the population with GFR 60 mL/
min/1.73 m2 [53]. It’s generally a non-proteinuric renal that could be at play here.
Dr. Dirks: My second question relates to the case.disease. The MDRD subset of PKD patients didn’t
achieve any benefit from dietary protein restriction and You stressed the value and importance of having models
that are relevant. Here’s an unusual case, acute renalblood pressure reduction, although I grant you, these
patients didn’t receive an ACE inhibitor. In addition, failure with cortical necrosis, with a background of pitu-
itary insufficiency, which might involve a lack of growththe subset of PKD patients reported by Maschio et al
[24] didn’t achieve any benefit from ACE inhibition in hormone and other pituitary hormones. What do we
know from the literature about various acute renal fail-that study. Could I push you a little further in terms of
focusing on PKD as a non-diabetic renal disease? Should ure models and renal protection?
Dr. Brenner: To the extent that we have follow-up,we treat it the same way as other renal diseases?
Dr. Brenner: In order to know how best to treat most acute renal failure doesn’t lead to chronic renal
failure. However, there are cases of acute renal failurepatients, we need evidence from randomized clinical tri-
als. We don’t have an explicit, robust trial directed exclu- that years later do present as chronic renal failure. Corti-
cal necrosis is one of the well-characterized causes. Theresively at PKD patients. In the trials you mentioned, PKD
patients were relatively few in number. Even if they are others, for example, patients with malignant hyper-
tension or scleroderma crisis who also exhibit an acutebenefited from a treatment, it would be difficult to detect
the benefit with the small number of patients enrolled component of injury that translates to profound loss of
renal function, but not all the nephrons are destroyed.and in the short period of time in which the study was
performed. You said these studies were negative. I think As in the patient discussed today, they often improve
transiently and then progress to renal failure.that’s too strong a statement. In my opinion, no interpre-
tation is possible given the small sample size and short Dr. Dirks: What is the implication for this form of
therapy globally? We know it’s going to be hard enoughstudy duration.
Dr. Jeffrey Stoff (Director, Renal Medicine, University in our own countries, Canada and the United States, to
get physicians to institute rigorous multifactorial strate-of Massachusetts Memorial Medical Center, Worcester,
Massachusetts): There’s some evidence that microalbu- gies for their patients with early renal disease. You and
I have been to many countries where there are no oppor-minuria alone is a cardiovascular risk factor independent
of intrinsic renal disease. Will you speculate as to tunities for renal replacement therapy. I was in West
Africa in November, 2001, a country of 20 million people.whether you think this is a reflection of the centrality of
angiotensin II in these settings or a non-angiotensin II Only 8 stations were available for dialysis, and only as
long as you could pay $100 for each dialysis. So howpathway reflecting the inflammatory process?
Dr. Brenner: Your first point, that microalbuminuria are these people going to institute secondary prevention
strategies?is a risk factor for cardiovascular events, has been docu-
mented in many settings. Is this angiotensin II driven? Dr. Brenner: This problem is desperate. Even in the
so-called developed world, if you look at the treatmentCertainly there is abundant evidence to support a role
for RAS activation, even at the earliest stages of diabe- of hypertension, you find that one-half the people don’t
know they’re hypertensive, and of those who do, onlytes, but establishing causality is not yet possible.
Dr. John Dirks (Professor of Medicine Emeritus, Uni- one-half are “well controlled.” There seems to be a cer-
tain casualness to our management strategy. Prescribingversity of Toronto, Toronto, Ontario, Canada): I have
three questions. The first concerns the additive effects of antihypertensive drugs requires that we set blood pres-
sure targets that must be achieved. Doctors have beenACE inhibitors and ARBs. As you pointed out for ACE
inhibitors, theoretically even when you block conversion in the business of writing ACE inhibitor prescriptions
for 20 years, yet we still have a growing ESRD problem.from angiotensin I to II with an ACE inhibitor, some
conversion still takes place by other mechanisms. There- How much of a dose did they prescribe? Low doses can
limit side effects but are not likely to provide maximalfore, you might think that an angiotensin receptor antag-
onist could be advantageous. Why are we seeing additive control of either blood pressure or proteinuria. I am
encouraged by guidelines coming from agencies such aseffects when the angiotensin receptor blockade should
in theory be sufficient? What is the mechanism involved? the American Diabetes Association, National Kidney
Foundation, Lupus, PKD Foundations, etc. They’re allDr. Brenner: I don’t know the answer, but I have
sleepless nights about it. One possibility is that the ACE setting goals of therapy for their kidney patients. Hope-
fully this will improve treatment strategies for more pa-inhibitor is not completely inhibiting angiotensin II for-
mation. Similarily, the receptor antagonist is not blocking tients at risk than was achieved previously. As to the
issue of applicability of these strategies in the developingall receptors or all angiotensin II binding to the receptors.
We know that the receptor for AT1 has polymorphisms. world, we must rely heavily on physician education, as
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you are doing so effectively through the International for drugs with very favorable safety profiles. Such drugs
could be approved for their demonstrated effects,Society of Nephrology’s (ISN) COMGAN program.
Dr. Lance Dworkin (Director, Division of Renal Dis- namely proteinuria reduction or slowing GFR decline.
Unless a reduction in ESRD is demonstrated, such drugseases, Rhode Island Hospital, Providence, Rhode Island):
I think most of us would accept your comprehensive should not be given the full designation as renoprotec-
tive, at least in my current thinking.strategy for renal protection. But you’re still a little bit
out in front of us in calling for the correction of anemia
Reprint requests to Dr. Barry M. Brenner, Brigham & Women’s
to a hemoglobin of 12.0. Are we really ready for this Hospital, 75 Francis Street, Boston, MA 02115.
E-mail: bbrenner@partners.orgrecommendation?
Dr. Brenner: Lance, the evidence thus far is limited.
We know from RENAAL and from the Medicare Data REFERENCES
Base that anemia is a risk factor for both renal and 1. Brenner BM: Nephrology Forum: Hemodynamically mediated
glomerular injury and the progressive nature of renal disease. Kid-cardiovascular events. Unfortunately, we do not yet have
ney Int 23:647–655, 1983an abundance of prospective, randomized, controlled tri-
2. Mackenzie HS, Taal MW, Luycks VA, Brenner BM: Adaptation
als to cite, although several have been or will soon be to nephron loss, in Brenner and Rector’s The Kidney (6th ed),
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gressive glomerular sclerosis in aging, renal ablation, and intrinsicDr. Nicolaos E. Madias (Dean ad interim, Tufts Uni-
renal disease. N Engl J Med 307:652–659, 1982
versity School of Medicine, Boston, Massachusetts): You 4. Brenner BM, Chertow GM: Congenital oligonephropathy and
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1988pathways that contribute to loss of renal function. Could
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7. Anderson S, Rennke HG, Brenner BM: Therapeutic advantageand PAI-1, and weigh their promise for nephroprotec-
of converting enzyme inhibitors in arresting progressive renal dis-tion?
ease associated with systemic hypertension in the rat. J Clin Invest
Dr. Brenner: There are many likely pathways to in- 77:1993–2000, 1986
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1817, 2000
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actions of angiotensins. Curr Opin Nephrol Hypertens 10:321–329,and molecules you mentioned, none has yet moved to
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